http://orcid.org/0000-0001-7492-8010
References
- Ataseven A, Ozturk P, Kucukosmanoglu I, et al. Kyrle’s disease. BMJ Case Rep. 2014;2014:bcr2013009905.
- Schreml S, Hafner C, Eder F, et al. Kyrle disease and acquired perforating collagenosis secondary to chronic renal failure and diabetes mellitus. Case Rep Dermatol. 2011;3:209–211.
- Nair PA, Jivani NB, Diwan NG. Kyrle’s disease in a patient of diabetes mellitus and chronic renal failure on dialysis. J Family Med Prim Care. 2015;4:284–286.
- Matsuzaki Y, Yokoyama S, Rokunohe A, et al. Successful treatment of Kyrle disease with narrowband ultraviolet B. J Dermatol. 2017;44:721–722.
- Saleh HA, Lloyd KM, Fatteh S. Kyrle’s disease. Effectively treated with isotretinoin. J Fla Med Assoc. 1993;80:395–397.
- Aram H, Even-Paz Z, Livshin R. Kyrle’s disease. Response to high-dose vitamin A. Cutis. 1982;30:753–755, 759.
- Akoglu G, Emre S, Sungu N, et al. Clinicopathological features of 25 patients with acquired perforating dermatosis. Eur J Dermatol. 2013;23:864–871.
- Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell us? Aust J Dermatol. 2013;54:157–162.